Royalty Pharma plc (FRA:RPD)

Market Cap	16.41B +22.3%
Revenue (ttm)	2.03B +5.1%
Net Income	656.62M -10.2%
EPS	1.52 -6.8%
Shares Out	n/a
PE Ratio	24.99
Forward PE	6.82
Dividend	0.77 (2.09%)
Ex-Dividend Date	Feb 20, 2026

Volume	n/a
Average Volume	42
Open	37.85
Previous Close	37.18
Day's Range	37.12 - 37.85
52-Week Range	25.73 - 39.07
Beta	n/a
RSI	57.48
Earnings Date	Feb 11, 2026

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 100
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RPD

Financial Performance

In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.

Financial numbers in USD